{"id":"NCT02672332","sponsor":"Novan, Inc.","briefTitle":"P3 Study in Acne Comparing Once Daily SB204 and Vehicle","officialTitle":"A Phase 3 Multi-Center, Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy, Tolerability and Safety of SB204 and Vehicle Gel Once Daily in the Treatment of Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-02-22","primaryCompletion":"2016-12","completion":"2016-12-21","firstPosted":"2016-02-03","resultsPosted":"2023-05-06","lastUpdate":"2023-07-24"},"enrollment":1307,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"SB204 4%","otherNames":["NVN1000"]},{"type":"DRUG","name":"Vehicle Gel","otherNames":["Placebo"]}],"arms":[{"label":"SB204 4%","type":"EXPERIMENTAL"},{"label":"Vehicle Gel","type":"PLACEBO_COMPARATOR"}],"summary":"This is a 12 week, multi-center, double-blinded, randomized, vehicle-controlled, parallel group, study to be conducted in approximately 1300 subjects with acne vulgaris in the US.","primaryOutcome":{"measure":"Absolute Change From Baseline in Inflammatory Lesion Counts","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"SB204 4%","deltaMin":-12.4,"sd":10.3},{"arm":"Vehicle Gel","deltaMin":-11.3,"sd":10.46}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":55,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":654},"commonTop":["Application site pain","Nasopharyngitis","Application site pruritus","Application site erythema","Application site dryness"]}}